chloroquine for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Huang ChiCTR2000029542		RCT	chloroquine	lopinavir/ritonavir	COVID 19 hospitalized	some concern	10/12	suggested	suggested 100 % increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
Chen_chloroquine		OBS	chloroquine	standard of care	COVID 19 hospitalized	critical	17/121	inconclusive
Huang		OBS	chloroquine	control	COVID 19 hospitalized	critical	197/176	suggested	suggested 5.1-fold increase in viral clearance by day 14 but with a very low degree of certainty due to critical risk of bias
COVID 19 all comers meta-analysis
Chen, ChiCTR2000030054 - Chloroquine ChiCTR2000030054		RCT	chloroquine	standard of care	COVID 19 all comers	high	18/12	inconclusive
COVID-19 mild to moderate meta-analysis
NCT04342650 NCT04342650		RCT	chloroquine	placebo	COVID-19 mild to moderate	NA	-/-	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis